Biliary tract cancer: state of the art and potential role of DNA damage repair.
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractBiliary tract cancers (BTCs), including cholangiocarcinoma, gallbladder cancer and ampullary cancers, are poor-prognosis malignancies. Most patients are diagnosed with advanced disease, when treatment is limited to palliative chemotherapy. First line chemotherapy is usually administered in the form of cisplatin and gemcitabine. Benefit from second line chemotherapy is still to be confirmed. Even though new systemic treatment targets have been recognised, especially in patients with intrahepatic cholangiocarcinoma (e.g. IDH and FGFR), there is an urgent need for novel treatment strategies. Genomic profiling of BTC is progressively becoming a reality which allows a better understanding of their biology and potential new targets. This review provides an insight into DNA Damage Repair (DDR) mechanisms, prevalence of DDR-deficient tumours in BTC, and the potential role of DDR in cancer development. Some form of DDR deficiency is expected to be present in around 25% of patients with BTC, and this knowledge could be exploited to potentially increase response to currently-available treatment strategies (chemotherapy, radiotherapy or immunotherapy). For patients with DDR-proficient tumours, drug inhibition of DDR could be instituted.
CitationBiliary tract cancer: state of the art and potential role of DNA damage repair. 2018, 70: 168-177 Cancer Treat Rev
JournalCancer Treatment Reviews
- Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
- Authors: Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY
- Issue date: 2019 Oct
- Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome.
- Authors: Cloyd JM, Chun YS, Ikoma N, Vauthey JN, Aloia TA, Cuddy A, Rodriguez-Bigas MA, Nancy You Y
- Issue date: 2018 Mar
- New Horizons for Precision Medicine in Biliary Tract Cancers.
- Authors: Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX
- Issue date: 2017 Sep
- Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
- Authors: Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, Primrose J, Valle JW
- Issue date: 2020 Mar
- Optimum chemotherapy for the management of advanced biliary tract cancer.
- Authors: Ghosn M, Kourie HR, El Rassy E, Chebib R, El Karak F, Hanna C, Nasr D
- Issue date: 2015 Apr 14